Tutorspedia

Pfizer: Letter From The Chairman Case Study Help Analysis With Solution Online

 
Glancing for case solution online puts together each minute information in one place along with the assistance of highly certified and professional tutors who has the ability to scan your mind from its core and improve the quality of education. They prove themselves best in answering your questions ranging from the simplest one to the toughest. Keeping in mind the catching power and understanding ability of every student we provide the required solutions bit by bit by working relentlessly so that everyone can gain full knowledge without any difficulty. For preparing the students for extreme conditions we provide different worksheets and practice papers through which they can solve every question coming in their way. Considering the social and economic conditions of the students we charge you the most reasonable prices in comparison to other online services.
 
This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to examine these decisions, the case provides excerpts from four Chairman’s letters to shareholders from Pfizer’s annual reports, followed by a description of the circumstances behind each letter. In the 2000 annual report, then-CEO Bill Steere discusses Pfizer’s rise to industry prominence with the acquisition of Warner-Lambert. In the 2003 report, new CEO Hank McKinnell discusses Pfizer’s performance goals and its acquisition of Pharmacia, which gave it control of anti-arthritis drug Celebrex. In the 2005 report, McKinnell discusses his decision to keep Celebrex on the market despite health risks. In the 2006 report, new CEO Jeff Kindler barely mentions McKinnell’s (controversial) early retirement and describes efforts to reform the company. The case closes in February 2009, just after Pfizer announces plans to acquire competitor Wyeth. Since 2000, Pfizer’s tremendous growth in assets through acquisitions has not translated into significant growth in net income or share price. In closing, students are asked what Kindler should write in the letter to shareholders to open Pfizer’s 2008 annual report.